Guardant Health, Inc. (GH)

NASDAQ: GH · Real-Time Price · USD
49.30
+0.01 (0.02%)
At close: Jun 16, 2025, 4:00 PM
50.00
+0.70 (1.42%)
After-hours: Jun 16, 2025, 7:51 PM EDT
0.02%
Market Cap 6.11B
Revenue (ttm) 774.00M
Net Income (ttm) -416.55M
Shares Out 123.89M
EPS (ttm) -3.38
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,688,823
Open 49.76
Previous Close 49.29
Day's Range 48.16 - 49.86
52-Week Range 20.14 - 52.92
Beta 1.38
Analysts Strong Buy
Price Target 54.35 (+10.24%)
Earnings Date Aug 6, 2025

About GH

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally. The company provides precision oncology testing services comprising Guardant360, a panel of genetic tests; Guardant360 LDT that measures 730+ genes and supports all guideline-recommended biomarkers; Guardant360 CDx Test, a liquid biopsy test; Guardant360 Response Test, a blood-only liquid biopsy; Guardant360 TissueNext Test, a tissue-based test with AI-powered PD-L1 detection; GuardantINFINITY Test that p... [Read more]

Sector Healthcare
IPO Date Oct 4, 2018
Employees 2,021
Stock Exchange NASDAQ
Ticker Symbol GH
Full Company Profile

Financial Performance

In 2024, Guardant Health's revenue was $739.02 million, an increase of 31.04% compared to the previous year's $563.95 million. Losses were -$436.37 million, -8.98% less than in 2023.

Financial Statements

Analyst Forecast

According to 20 analysts, the average rating for GH stock is "Strong Buy." The 12-month stock price forecast is $54.35, which is an increase of 10.24% from the latest price.

Price Target
$54.35
(10.24% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Guardant Health Wins Fast Company's 2025 World Changing Ideas Award for Shield Blood Test for Colorectal Cancer Screening

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced its Shield blood test for colorectal cancer (CRC) screening has been named...

6 days ago - Business Wire

New Study Published in ESMO Open Highlights Guardant Reveal's Performance in Detecting Minimal Residual Disease in Patients with Early-Stage Breast Cancer

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced results from the LIBERATE study published in ESMO Open. The results in the...

7 days ago - Business Wire

Why Is Cancer Diagnostic Guardant Health Stock Trading Higher On Tuesday?

Guardant Health, Inc. GH stock is trading higher on Tuesday after the U.S. Food and Drug Administration (FDA) granted Breakthrough Device designation to the company's Shield multi-cancer detection (MC...

13 days ago - Benzinga

FDA Grants Breakthrough Device Designation to Guardant Health's Shield Multi-Cancer Detection (MCD) Test

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that its Shield multi-cancer detection (MCD) test has been granted Breakth...

13 days ago - Business Wire

National Comprehensive Cancer Network (NCCN) Updates Colorectal Cancer Screening Guidelines to Include Shield Blood-Based Screening

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the National Comprehensive Cancer Network (NCCN) has included the Shi...

14 days ago - Business Wire

SERENA-6 Phase III Trial Demonstrates Clinical Value of Guardant360 CDx Test to Detect Emergence of Endocrine Resistance and Inform a Switch in Therapy Before Radiological Disease Progression in Advanced Breast Cancer

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the results of the Phase III SERENA-6 trial - sponsored by AstraZenec...

14 days ago - Business Wire

In Largest Molecular Residual Disease (MRD) Study in Colon Cancer, Guardant Reveal Testing Prior to Chemotherapy Provides Robust Stratification for Risk of Disease Recurrence and Survival to Enable Timely Treatment Decisions

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, and its research collaborators today presented results of the largest study to date evalua...

16 days ago - Business Wire

Guardant Health Introduces Nearly a Dozen Groundbreaking Smart Liquid Biopsy Applications for Guardant360 Liquid Test

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced major new features for the Guardant 360® Liquid test that greatly expand i...

20 days ago - Business Wire

Guardant Health and Collaborators to Present Over 19 Studies Demonstrating Role of Liquid Biopsy in Advancing Precision Oncology at 2025 ASCO Annual Meeting

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company and its research collaborators will present data from more tha...

25 days ago - Business Wire

Guardant Health Introduces Comprehensive Immunohistochemistry Testing for Solid Tumors

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the addition of a full suite of immunohistochemistry (IHC) testing to the ...

26 days ago - Business Wire

Guardant Health Introduces Hereditary Cancer Testing to Identify Inherited Predispositions to Certain Types of Cancer

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the launch of the Guardant Hereditary Cancer test, a germline test that id...

27 days ago - Business Wire

Guardant Health to Participate in Upcoming Investor Conferences

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will be participating in the following investor conferences. B...

5 weeks ago - Business Wire

TIME Names Guardant Health Co-CEOs to 2025 TIME100 Health List of the 100 Most Influential People in Global Health This Year

PALO ALTO, Calif.--(BUSINESS WIRE)--Today TIME named to its 2025 TIME100 Health list co-CEOs Helmy Eltoukhy and AmirAli Talasaz of Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology comp...

5 weeks ago - Business Wire

Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that on April 22, 2025, the Compensation Committee of Guardant's Board of ...

5 weeks ago - Business Wire

Guardant Health: Tailwinds Are Beginning To Impact The Financials

Guardant Health handily beat Q1 expectations and meaningfully increased full-year growth expectations. Guardant also continues to benefit from positive developments in relation to pricing, regulatory ...

6 weeks ago - Seeking Alpha

Guardant Health, Inc. (GH) Q1 2025 Earnings Call Transcript

Guardant Health, Inc. (NASDAQ:GH) Q1 2025 Earnings Conference Call April 30, 2025 4:30 PM ET Company Participants Zarak Khurshid - Vice President of Investor Relations Helmy Eltoukhy - Chairman and C...

6 weeks ago - Seeking Alpha

Guardant Health Reports First Quarter 2025 Financial Results and Increases 2025 Revenue Guidance

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today reported financial results for the quarter ended March 31, 2025. First Quarter 2025 ...

6 weeks ago - Business Wire

Guardant Health Presents Data Demonstrating Strong Performance of Shield Multi-Cancer Detection Test Across 10 Tumor Types

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, presented data today from a study showing that its methylation-based Shield™ multi-cancer ...

6 weeks ago - Business Wire

CORRECTING and REPLACING Guardant Health Launches Guardant360 Tissue, First Tissue Molecular Profiling Test with Comprehensive Multiomic Analysis to Provide a More Complete View of Cancer

PALO ALTO, Calif.--(BUSINESS WIRE)--Throughout release, "exome-wide" should read as "genome-wide". The updated release reads: GUARDANT HEALTH LAUNCHES GUARDANT360 TISSUE, FIRST TISSUE MOLECULAR PROFIL...

7 weeks ago - Business Wire

Guardant Health Launches Guardant360 Tissue, First Tissue Molecular Profiling Test with Comprehensive Multiomic Analysis to Provide a More Complete View of Cancer

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the launch of Guardant360® Tissue, the first molecular profiling test for ...

7 weeks ago - Business Wire

Guardant Health Announces Strategic Collaboration With Pfizer to Support Development and Commercialization of New Cancer Therapies Using Guardant Infinity Smart Liquid Biopsy Platform

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced a strategic collaboration with Pfizer, Inc. (NYSE: PFE), to support the de...

Other symbols: PFE
7 weeks ago - Business Wire

Guardant Health to Present Data Highlighting Advances in Multi-Cancer Detection and Liquid and Tissue Molecular Profiling at AACR

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will present 18 abstracts, including four oral sessions, showcasing adv...

7 weeks ago - Business Wire

Guardant Health to Report First Quarter 2025 Financial Results on April 30, 2025

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the first quarter 2025 after market c...

2 months ago - Business Wire

Guardant Health and Bayshore HealthCare Partner to Expand Access to Advanced Precision Oncology Testing in Canada

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it has entered into an agreement with Bayshore HealthCare, a leading home ...

2 months ago - Business Wire

Guardant Health's Shield Blood Test Now Covered for VA Community Care Beneficiaries

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced its Shield™ blood test for colorectal cancer (CRC) screening is now covere...

2 months ago - Business Wire